Dario Neri is co-founder and President of the Scientific Advisory Board of Philogen. He graduated in Chemistry at the Scuola Normale Superiore in Pisa and obtained his PhD in Chemistry from the ETH Zürich, under the supervision of Prof. Kurt Wüthrich, winner of the Nobel Prize for Chemistry in 2002. For his dissertation, he was awarded the Silver Medal of ETH. After a 5 years post-doctoral research position in the lab of 2018 Chemistry Nobel Price Winner Sir Gregory Winter at the Cambridge Centre of Protein Engineering in Cambridge, UK, he returned to ETH Zürich in 1996 as Assistant Professor in Molecular Structure Biology.
Since 1999, he has been a Professor of Biomacromolecules in the department of Chemistry and Applied Biosciences at ETH Zürich. The research of the Neri group focuses on the engineering of therapeutic antibodies for the treatment of cancer and of chronic inflammatory conditions. Other research activities include the development of DNA-encoded chemical libraries and of small molecule-drug conjugates. Furthermore, the group uses mass spectrometry methodologies for the discovery of vascular markers of disease and for HLA peptidome analysis.
Dr. Neri is the recipient of the ISOBM Abbott Prize 2000, of the Amgen-Dompé Biotec Award 2000, of the Mangia d'Oro 2001, of the Prous Award 2006 of the European Federation of Medicinal Chemistry, of the Robert-Wenner-Prize 2007 of the Swiss Cancer League, of the SWISS BRIDGE Award 2008, of the Prix Mentzer 2011 of the French Medicinal Chemistry Society, of the Phoenix Prize 2014 and of an ERC Advanced Grant 2015. Prof. Neri is author of more than 400 publications in international scientific journals.
Guido Guidi brings 35 years of experience in the pharmaceutical industry.
He received his medical training at the University of Milan, where he obtained his MD in 1979. He continued his specialized training in Immunology and Allergology, as well as in Rheumatology in Milan until 1989. In parallel, he served as a medical advisor for Smith Kline and Roussel UCLAF and was medical director at Sharper Italia (Roussel UCLAF Group) from 1986 to 1989.
In 1990, Guido moved to Sandoz Italy to lead the Immunology and Transplant Business Unit for two years and subsequently the Unit for Specialty Products. After having received some education in business administration, he transitioned to Novartis in 2000, where he was Head of Oncology, initially for southern Europe, and from 2002 for entire Europe. During the next ten years, Guido was responsible for bringing various drugs from clinical development to market including Zometa, Femara, Glivec, Sandostatin and Jakavi. As member of the Novartis deal committee, he further played a key role in various partnering operations (e.g., Ruxolitinib from Incyte and Erenumab from Amgen). At the end of 2012, Guido became Head of Pharma Europe, where he was leading Novartis’ General Medicines Business in Europe marketing several key products including Cosentyx, Entresto, Lucentis, Gilenya, Xolair, Ultibro, Seebri, Galvus, Exforge and others. During this four-year period, Guido was overseeing a staff of more than 7,000 employees operating in more than 50 countries, including Russia and Israel. At Novartis, Guido originated and chaired the first edition of Bioupper, the Novartis accelerator for early-stage projects in Italy. He was also Chairman of the Novartis European Executive Committee and a member of the Innovation Management Board responsible for the Pharma division’s R&D program.
Guido is currently Chairman, Co-Founder and Managing Partner of the technology transfer company AurorA-TT and he is teaching professor for the master program in Pharmaceutical Medicine organized by the University of Milan and Mario Negri Institute. In addition, he is board member of the Zambon Group, Genenta and Tethis, as well as scientific advisory board member of Italfarmaco.
Wolfgang Berdel received his medical training at the Universities of Hamburg, Munich and Freiburg, where he obtained his MD in 1979. He was trained in cell biology and immunology at the Max Planck Institute for Immunobiology in Freiburg, received training in Internal Medicine, Hematology and Oncology at the Technische Universitaet of Munich, was Visiting Assoc. Professor in the Division of Hematology and Oncology at Emory University School of Medicine in Atlanta, Georgia, USA (1986-1988) and Assoc. Professor at the Benjamin Franklin Hospital of the Free University Berlin until 1997. From 1997 - 2017 Dr. Berdel served as Professor of Medicine and Chairman of the Department for Medicine/Hematology and Oncology, Hemostaseology and Pneumology at the University of Muenster (WWU), Germany. He served as Vice-President for Research of the University between 2002 and 2006. Upon other academic functions Dr. Berdel served as chairman of the Phase I/II Study Group of the German Cancer Society, as a member and section chairman of a Fachkollegium in the Deutsche Forschungsgemeinschaft (DFG), and for 5 years as a member of the National Drug Approval Board in the Bundesamt für Arzneimittel und Medizinprodukte (BfArM). He is currently chairman of the joined Ethical Board of the Physicians Chamber of Westfalia-Lippe and the WWU.
Dr. Berdel’s scientific interest is in preclinical development and early clinical evaluation of cytotoxic drugs and biologically active peptides modifying tumor growth. He co-developed the ether lipids (alkyl-lysophospholipids and thioether-phospholipids) and conjugates, a new class of anticancer drugs with the cellular membranes as their main target and introduced this new class of compounds into early clinical trials. His laboratory was the first to demonstrate extrahematopoietic activity of hematopoietic cytokines such as IL-3, GM-CSF, and G-CSF on the clonal growth of solid tumor cells. Dr. Berdel´s translational activities led to multiple phase I and phase II trials and as a co-chairman of the European Study Alliance Leukemia (SAL) he introduced signal transduction inhibitors such as Sorafenib into randomized clinical trials in acute myeloid leukemia (AML). His current research interest is in the field of vascular targeting of solid tumors.
Dr. Berdel is author and co-author of more than 600 scientific publications. He has received several awards including the Farmitalia Carlo Erba Award of the Association for Medical Oncology (AIO, 1985), a Heisenberg fellowship by the DFG (1987), the German Cancer Award of the German Cancer Society (1996), the Hippocrates Oath Award, 2nd World Congr. on Adv. in Oncol., Athens (1997), and the Science Award of the AIO (2002), the Phoenix Pharmazie Wissenschaftspreis (2014). Dr. Berdel held the Raisa Gorbacheva Memorial Lecture, St. Petersburg (2011).
Dr. Berdel´s support for associates helped 20 collegues completing the Habilitation, 12 obtaining full professorships with 4 department chairs in Medicine and 2 division chairs in Biology.
Cornelia Halin Winter, born on 4th of October 1974 in Zurich, Switzerland, studied biochemistry at ETH Zurich (1993 – 1998). After obtaining her diploma, she spent 6 months working as an intern in the Department of Molecular Oncology at Genentech Inc., San Francisco, USA. From 1999 – 2002 she performed her PhD thesis in the laboratory of Prof. Dr. Dario Neri at the Institute of Pharmaceutical Sciences of ETH Zurich, working on immunocytokines and targeted tumor therapy. Her dissertation was awarded the ETH Zurich Silver Medal. From 2002 -2005, Cornelia Halin Winter performed post-doctoral research in the laboratory of Prof. Dr. Ulrich von Andrian at Harvard Medical School, Boston, USA, working in the field of leukocyte trafficking. In 2005 she returned to the Institute of Pharmaceutical Sciences of ETH Zurich for a second post-doc and subsequent group leader position in the laboratory of Prof. Dr. Michael Detmar in the field of lymphatic vessel biology. From 2008 - 2014 she worked as an Assistant Professor at the same Institute.
At present, Cornelia Halin Winter holds the position of Associate Professor in the Institute of Pharmaceutical Sciences of ETH Zurich. Her research focuses on leukocyte migration and vascular biology in the context of inflammation and tumor growth. An important goal of her research is to identify and validate new (adhesion) molecules, which could serve as therapeutic targets to modulate immune responses.